Literature DB >> 34239133

Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection.

Rebekah M Dedrick1, Krista G Freeman1, Jan A Nguyen2, Asli Bahadirli-Talbott2, Bailey E Smith1, Andrew E Wu2, Aaron S Ong2, Cheng Ting Lin3, Lisa C Ruppel4, Nicole M Parrish5, Graham F Hatfull6, Keira A Cohen7.   

Abstract

An 81-year-old immunocompetent patient with bronchiectasis and refractory Mycobacterium abscessus lung disease was treated for 6 months with a three-phage cocktail active against the strain. In this case study of phage to lower infectious burden, intravenous administration was safe and reduced the M. abscessus sputum load tenfold within one month. However, after two months, M. abscessus counts increased as the patient mounted a robust IgM- and IgG-mediated neutralizing antibody response to the phages, which was associated with limited therapeutic efficacy.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34239133      PMCID： PMC8571776          DOI： 10.1038/s41591-021-01403-9

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  5 in total

1.  The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation.

Authors:  N K JERNE; P AVEGNO
Journal:  J Immunol       Date:  1956-03       Impact factor: 5.422

2.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections.

Authors:  C Kamme
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-12

5.  Mycobacterium abscessus Strain Morphotype Determines Phage Susceptibility, the Repertoire of Therapeutically Useful Phages, and Phage Resistance.

Authors:  Rebekah M Dedrick; Bailey E Smith; Rebecca A Garlena; Daniel A Russell; Haley G Aull; Vaishnavi Mahalingam; Ashley M Divens; Carlos A Guerrero-Bustamante; Kira M Zack; Lawrence Abad; Christian H Gauthier; Deborah Jacobs-Sera; Graham F Hatfull
Journal:  mBio       Date:  2021-03-30       Impact factor: 7.867
  5 in total
  15 in total

1.  Complete Genome Sequence of Mycobacteriophage IgnatiusPatJac.

Authors:  Olivia Jacobs; Nikki Gentle; Christopher Ealand; Bavesh Kana
Journal:  Microbiol Resour Announc       Date:  2022-09-21

Review 2.  Biological foundations of successful bacteriophage therapy.

Authors:  Carola Venturini; Aleksandra Petrovic Fabijan; Alicia Fajardo Lubian; Stefanie Barbirz; Jonathan Iredell
Journal:  EMBO Mol Med       Date:  2022-05-27       Impact factor: 14.260

Review 3.  Mycobacteriophages: From Petri dish to patient.

Authors:  Graham F Hatfull
Journal:  PLoS Pathog       Date:  2022-07-07       Impact factor: 7.464

4.  Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease.

Authors:  Rebekah M Dedrick; Krista G Freeman; Jan A Nguyen; Asli Bahadirli-Talbott; Mitchell E Cardin; Madison Cristinziano; Bailey E Smith; Soowan Jeong; Elisa H Ignatius; Cheng Ting Lin; Keira A Cohen; Graham F Hatfull
Journal:  Open Forum Infect Dis       Date:  2022-04-12       Impact factor: 4.423

5.  Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus.

Authors:  Matt D Johansen; Matthéo Alcaraz; Rebekah M Dedrick; Françoise Roquet-Banères; Claire Hamela; Graham F Hatfull; Laurent Kremer
Journal:  Dis Model Mech       Date:  2021-09-16       Impact factor: 5.758

Review 6.  Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment.

Authors:  Christopher G Shield; Benjamin M C Swift; Timothy D McHugh; Rebekah M Dedrick; Graham F Hatfull; Giovanni Satta
Journal:  Microorganisms       Date:  2021-11-16

7.  Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth.

Authors:  Stephen T Abedon; Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak
Journal:  Pharmaceuticals (Basel)       Date:  2021-10-03

8.  Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study.

Authors:  Jolien Onsea; Virginia Post; Tim Buchholz; Hella Schwegler; Stephan Zeiter; Jeroen Wagemans; Jean-Paul Pirnay; Maya Merabishvili; Matteo D'Este; Stijn G Rotman; Andrej Trampuz; Michael H J Verhofstad; William T Obremskey; Rob Lavigne; R Geoff Richards; T Fintan Moriarty; Willem-Jan Metsemakers
Journal:  Microbiol Spectr       Date:  2021-12-15

Review 9.  Phage therapy for secondary bacterial infections with COVID-19.

Authors:  Nannan Wu; Li-Kuang Chen; Tongyu Zhu
Journal:  Curr Opin Virol       Date:  2021-11-09       Impact factor: 7.090

10.  A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display.

Authors:  Krista G Freeman; Katherine S Wetzel; Yu Zhang; Kira M Zack; Deborah Jacobs-Sera; Sara M Walters; Dominique J Barbeau; Anita K McElroy; John V Williams; Graham F Hatfull
Journal:  Microorganisms       Date:  2021-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.